Gastroenterology
Volume 138, Issue 1 , Pages 123-135.e2 , January 2010

Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection

  • Gregory J. Dore

      Affiliations

    • National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    • HIV/Immunology/Infectious Diseases Clinical Services Unit, St Vincent's Hospital, Sydney, Australia
    • Corresponding Author InformationReprint requests Address requests for reprints to: Professor Gregory J. Dore, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Level 2, 376 Victoria Street, Darlinghurst, New South Wales, 2010 Australia. fax: (61) 2-9385-0876
    • ,
  • Margaret Hellard

      Affiliations

    • Burnet Institute, Melbourne, Australia
    • Infectious Diseases Unit, The Alfred Hospital, Melbourne, Australia
    • ,
  • Gail V. Matthews

      Affiliations

    • National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    • HIV/Immunology/Infectious Diseases Clinical Services Unit, St Vincent's Hospital, Sydney, Australia
    • ,
  • Jason Grebely

      Affiliations

    • National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    • ,
  • Paul S. Haber

      Affiliations

    • Drug Health Services, Royal Prince Alfred Hospital, Sydney, Australia
    • Central Clinical School, University of Sydney, Sydney, Australia
    • ,
  • Kathy Petoumenos

      Affiliations

    • National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    • ,
  • Barbara Yeung

      Affiliations

    • National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    • ,
  • Philippa Marks

      Affiliations

    • National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    • ,
  • Ingrid van Beek

      Affiliations

    • Kirketon Road Centre, Sydney, Australia
    • ,
  • Geoffrey McCaughan

      Affiliations

    • Central Clinical School, University of Sydney, Sydney, Australia
    • Royal Prince Alfred Hospital, Sydney, Australia
    • ,
  • Peter White

      Affiliations

    • School of Medical Sciences, University of New South Wales, Sydney, Australia
    • ,
  • Rosemary French

      Affiliations

    • Burnet Institute, Melbourne, Australia
    • ,
  • William Rawlinson

      Affiliations

    • School of Medical Sciences, University of New South Wales, Sydney, Australia
    • Virology Division, SEALS Microbiology, Prince of Wales Hospital, Sydney, Australia
    • ,
  • Andrew R. Lloyd

      Affiliations

    • School of Medical Sciences, University of New South Wales, Sydney, Australia
    • ,
  • John M. Kaldor

      Affiliations

    • National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    • ,
  • Australian Trial In Acute Hepatitis C Study Group

Received 18 June 2009 ,Accepted 15 September 2009.

References 

  1. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13:34–41
  2. Thein HH, Krahn M, Kaldor JM, et al. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol. 2005;100:643–651
  3. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001;34:809–816
  4. Kamal SM, Fouly AE, Kamel RR, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology. 2006;130:632–638
  5. De Rosa FG, Bargiacchi O, Audagnotto S, et al. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C. J Antimicrob Chemother. 2006;57:360–363
  6. Santantonio T, Fasano M, Sinisi E, et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol. 2005;42:329–333
  7. Wiegand J, Buggisch P, Boecher W, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology. 2006;43:250–256
  8. Kamal SM, Moustafa KN, Chen J, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology. 2006;43:923–931
  9. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001;345:1452–1457
  10. Kamal SM, Ismail A, Graham CS, et al. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology. 2004;39:1721–1731
  11. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125:80–88
  12. Licata A, Di Bona D, Schepis F, et al. When and how to treat acute hepatitis C?. J Hepatol. 2003;39:1056–1062
  13. Santantonio T, Wiegand J, Gerlach JT. Acute hepatitis C: current status and remaining challenges. J Hepatol. 2008;49:625–633
  14. Darke S, Hall W, Wodak A, et al. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Br J Addict. 1992;87:733–742
  15. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33quiz 34–57
  16. Henry JD, Crawford JR. The short-form version of the Depression Anxiety Stress Scales (DASS-21): construct validity and normative data in a large non-clinical sample. Br J Clin Psychol. 2005;44:227–239
  17. White PA, Grebely J, Flynn J, et al. Natural history of HCV superinfection and reinfection. [abstract 1057] Hepatology. 2008;48(Suppl 4):779A
  18. Calleri G, Cariti G, Gaiottino F, et al. A short course of pegylated interferon-alpha in acute HCV hepatitis. J Viral Hepat. 2007;14:116–121
  19. Broers B, Helbling B, Francois A, et al. Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol. 2005;42:323–328
  20. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35–S46
  21. McHutchison JG, Fried MW. Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin Liver Dis. 2003;7:149–161
  22. Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol. 2007;19:741–747
  23. Matthews GV, Hellard M, Haber P, et al. Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis. 2009;48:650–658
  24. Vogel M, Nattermann J, Baumgarten A, et al. Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. Antivir Ther. 2006;11:1097–1101
  25. Gilleece YC, Browne RE, Asboe D, et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr. 2005;40:41–46
  26. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438–450
  27. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292:2839–2848

 Conflicts of interest These authors disclose the following: Gregory Dore, G.M., and J. Kaldor have received research support from Roche Pharmaceuticals; Gregory Dore is on the speaker's bureau for Roche Pharmaceuticals; Gregory Dore and G.M. are members of the advisory board for Roche Pharmaceuticals; Gregory Dore, P. Marks, and B. Yeung have received travel grants from Roche Pharmaceuticals; Gregory Dore is a consultant/advisor for Schering Plough, Tibotec, and Abbott; and G.M. is a consultant/advisor for Schering Plough, Novartis, and Astellar. The remaining authors disclose no conflicts.

 Funding This study was funded by the National Institutes of Health (grant RO1 DA 15999-01). The National Centre in HIV Epidemiology and Clinical Research is funded by the Australian Government Department of Health and Ageing and is affiliated with the Faculty of Medicine, University of New South Wales. Roche Pharmaceuticals supplied financial support for pegylated IFN alfa-2a/ribavirin. Gregory Dore, P. Haber, and A. Lloyd were supported by National Health and Medical Research Council Practitioner Research Fellowships; M. Hellard was supported by a National Health and Medical Research Council Career Development Award and a VicHealth Senior Research Fellowship; J. Grebely was supported by Postdoctoral fellowships from the Canadian Institutes of Health Research and the National Canadian Research Training Program in Hepatitis C; R. French was supported by a National Health and Medical Research Council Industry fellowship; and J. Kaldor was supported by National Health and Medical Research Council Research Fellowship.

PII: S0016-5085(09)01660-6

doi: 10.1053/j.gastro.2009.09.019

Gastroenterology
Volume 138, Issue 1 , Pages 123-135.e2 , January 2010

Article Tools

* Image Usage & Resolution